Epco, Zanu, Ritux for R/R FL or MZL
Epco, Zanu, Ritux for R/R FL or MZL
Recruiting · NCT06563596 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Epco, Zanu, Ritux for R/R FL or MZL | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-25 | NCT06563596 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BeiGene | 47 |
| Genmab | 54 |
| Reid Merryman, MD | 3 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 60 |
| The Ohio State University Wexner Medical Center | Columbus | United States | 102 |